[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kaposis-sarcoma-associated-herpesvirus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kaposis-sarcoma-associated-herpesvirus-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100534222","phase-4-the-effects-of-sirolimus-in-patients-with-dilated-cardiomyopathy-infected-with-kaposi-sarcoma-associated-virus-100534222",false,"NCT06236022","The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus","SDCMK","Inclusion Criteria:\n\n* 18 to 70 years of age;\n* Diagnosed as dilated cardiomyopathy. Specifically, (i) left ventricular ejection fraction \\\u003C45% (\\>2 SD) and\u002For fractional shortening \\\u003C25% (\\>2 SD), as ascertained by echocardiography, radionuclide scanning, or cardiac magnetic resonance imaging; (ii) left ventricular end-diastolic diameter \\>117% of the predicted value corrected for age and body surface area (Henry's formula), which corresponds to 2 SD of the predicted normal limit +5%; and (iii) In the absence of severe coronary artery disease or valvular disease.\n* KSHV DNA seropositivity;\n* Patients are voluntary and signed informed consent.\n\nExclusion Criteria:\n\n* Allergic to rapamycin or its derivatives；\n* The proportion of neutrophils less than 0.5\\*10\\^9\u002FL or platelet less than 2.5\\*10\\^10\u002FL;\n* Pregnant women or plan to;\n* Participate in any drug clinical trials within 3 months;\n* Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients);\n* Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions;\n* Patients were not optimally managed.","ALL","18 Years","70 Years",{"count":20,"type":21},276,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.",[27,28],"Dilated Cardiomyopathy","Kaposi's Sarcoma-Associated Herpesvirus Infection","RECRUITING","2024-01-24",{"date":32,"type":33},"2024-02-01","ACTUAL",{"date":35,"type":33},"2024-01-01",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Tongji Hospital","OTHER"]